Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Avalo Therapeutics, Inc.AVTX · Entity 4936 | Director · Chief Executive Officer | October 01, 2021 | October 04, 2021 |
| Phathom Pharmaceuticals, Inc.PHAT · Entity 5177 | Director | May 19, 2026 | May 21, 2026 |
| Vanda Pharmaceuticals Inc.VNDA · Entity 5861 | Director | June 13, 2019 | June 17, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Avalo Therapeutics, Inc.
Report date October 01, 2021 · Filed October 04, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.25 · Expires 2031-10-01 | Direct | 78,116 |
Reported balance
After 2021-10-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-10-01 · Grant · Acquired 78,116 · Balance 78,116 F1: 100% of this stock option will immediately vest on the date that it is granted. If employment is terminated prior to the end of the calendar quarter in which the option was granted, the number of shares underlying such stock option that reflects the percentage of calendar days remaining in such calendar quarter after such employment termination date shall be forfeited and deemed cancelled. |
Filing footnotes · ownership attribution and instrument terms
F1: 100% of this stock option will immediately vest on the date that it is granted. If employment is terminated prior to the end of the calendar quarter in which the option was granted, the number of shares underlying such stock option that reflects the percentage of calendar days remaining in such calendar quarter after such employment termination date shall be forfeited and deemed cancelled.
Phathom Pharmaceuticals, Inc.
Report date May 19, 2026 · Filed May 21, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 63,920 |
Reported balance
After 2026-05-19 transaction · row 1
1 source rowRow 1 · 2026-05-19 · Grant · Acquired 24,122 · Balance 63,920 F1: The Restricted Stock Units ("RSUs") were granted on May 19, 2026, pursuant to the Issuer's Non-Employee Director Compensation Program. 100% of the total number of RSUs granted shall vest on the first to occur of (A) the first anniversary of the date of grant or (B) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuing service on the Board through such vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: The Restricted Stock Units ("RSUs") were granted on May 19, 2026, pursuant to the Issuer's Non-Employee Director Compensation Program. 100% of the total number of RSUs granted shall vest on the first to occur of (A) the first anniversary of the date of grant or (B) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuing service on the Board through such vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer.
Vanda Pharmaceuticals Inc.
Report date June 13, 2019 · Filed June 17, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 15,000 |
Reported balance
After 2019-06-13 transaction · row 1
1 source rowRow 1 · 2019-06-13 · Grant · Acquired 5,000 · Balance 15,000 F1: Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 100% of the shares subject to this RSU will vest on June 13, 2020, provided that the Reporting Person has provided continuous service to the Issuer through the vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.04 · Expires 2029-06-12 | Direct | 10,000 |
Reported balance
After 2019-06-13 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2019-06-13 · Grant · Acquired 10,000 · Balance 10,000 F2: This option vests and becomes exercisable with respect to 100% of the option shares on June 13, 2020, provided that the Reporting Person has provided continuous service to the Issuer through the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 100% of the shares subject to this RSU will vest on June 13, 2020, provided that the Reporting Person has provided continuous service to the Issuer through the vesting date.
F2: This option vests and becomes exercisable with respect to 100% of the option shares on June 13, 2020, provided that the Reporting Person has provided continuous service to the Issuer through the vesting date.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Aevi Genomic Medicine, LLC
Report date June 09, 2020 · Filed June 11, 2020
Section 16 reporting ended · disclosed 2020-02-05. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 175,746 |
Reported balance
After 2020-06-09 transaction · row 1
1 source rowRow 1 · 2020-06-09 · Purchase · Acquired 100,000 · Balance 175,746 |
Sage Therapeutics, Inc.
Report date July 31, 2025 · Filed July 31, 2025
Section 16 reporting ended · disclosed 2025-07-31. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.77 · Expires 2035-06-10 | Direct | 0 |
Reported balance
After 2025-07-31 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-07-31 · Disposition to issuer · Disposed 21,500 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 13, 2025, among Sage Therapeutics, Inc. (the "Issuer"), Supernus Pharmaceuticals, Inc. ("Parent"), and Saphire, Inc., a wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a cash tender offer to purchase all outstanding shares of common stock of the Issuer (each, a "Share") for (i) $8.50 per Share in cash (the "Closing Amount"), plus (ii) one contingent value right ("CVR") per Share, each without interest and subject to the withholding of applicable taxes, and thereafter merged with and into the Issuer, effective as of July 31, 2025 (the effective time of the merger, the "Effective Time"). F2: (Continued from footnote 1) Each CVR represents the right to receive up to $3.50 per Share in cash upon the satisfaction of specified milestones, as described in the Form 8-K filed by the Issuer with the Securities and Exchange Commission on June 16, 2025. F3: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Shares (a "Company Option") then outstanding and unexercised, whether or not vested, which had a per Share exercise price less than the Closing Amount was deemed fully vested and cancelled and converted into the right to receive (i) a cash payment (without interest and subject to the withholding of applicable taxes) equal to the product of (a) the excess of the Closing Amount over the per Share exercise price of such Company Option, multiplied by (b) the total number of Shares subject to such Company Option immediately prior to the Effective Time, plus (ii) one CVR for each Share subject to such Company Option immediately prior to the Effective Time. Each Company Option, whether or not vested, which had a per Share exercise price greater than or equal to the Closing Amount was cancelled with no consideration payable in respect thereof. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 13, 2025, among Sage Therapeutics, Inc. (the "Issuer"), Supernus Pharmaceuticals, Inc. ("Parent"), and Saphire, Inc., a wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a cash tender offer to purchase all outstanding shares of common stock of the Issuer (each, a "Share") for (i) $8.50 per Share in cash (the "Closing Amount"), plus (ii) one contingent value right ("CVR") per Share, each without interest and subject to the withholding of applicable taxes, and thereafter merged with and into the Issuer, effective as of July 31, 2025 (the effective time of the merger, the "Effective Time").
F2: (Continued from footnote 1) Each CVR represents the right to receive up to $3.50 per Share in cash upon the satisfaction of specified milestones, as described in the Form 8-K filed by the Issuer with the Securities and Exchange Commission on June 16, 2025.
F3: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Shares (a "Company Option") then outstanding and unexercised, whether or not vested, which had a per Share exercise price less than the Closing Amount was deemed fully vested and cancelled and converted into the right to receive (i) a cash payment (without interest and subject to the withholding of applicable taxes) equal to the product of (a) the excess of the Closing Amount over the per Share exercise price of such Company Option, multiplied by (b) the total number of Shares subject to such Company Option immediately prior to the Effective Time, plus (ii) one CVR for each Share subject to such Company Option immediately prior to the Effective Time. Each Company Option, whether or not vested, which had a per Share exercise price greater than or equal to the Closing Amount was cancelled with no consideration payable in respect thereof.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 17, 2017 Filed Oct 18, 2017 16:17 UTC | Aevi Genomic Medicine, LLC GNMX · Entity 148532 | PurchaseCommon Stock | 119,047 | $1.26 | $149,999.22 |
DisclosureSEC source: 0001144204-17-053032 · tv477171_4.xml · nonDerivative · entry 1 COLA MICHAEL F · CIK 0001188940 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 218,483 Read SEC document |
| August 11, 2017 Filed Aug 15, 2017 16:15 UTC | Aevi Genomic Medicine, LLC GNMX · Entity 148532 | GrantStock Option (Right to Purchase) · Derivative | 500,000 | $0.00 Strike: $1.32 | $0.00 |
DisclosureSEC source: 0001144204-17-043507 · v473385_form4.xml · derivative · entry 1 COLA MICHAEL F · CIK 0001188940 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500,000 Underlying: Common Stock · 500,000 shares Expires 2027-08-11 F1 · derivative.exercise_date: The option award vests and becomes exercisable as follows (rounded up to the nearest whole share of common stock): one-third on August 11, 2018, then in 24 equal monthly installments on the 11th day of each subsequent calendar month, subject to the reporting person's continued service with the issuer. Read SEC document |
| August 11, 2017 Filed May 16, 2018 16:27 UTC Amendment | Aevi Genomic Medicine, LLC GNMX · Entity 148532 | GrantStock Option (Right to Purchase) · Derivative | 50,000 | $0.00 Strike: $1.32 | $0.00 |
DisclosureSEC source: 0001192482-18-000222 · edgar.xml · derivative · entry 1 COLA MICHAEL F · CIK 0001188940 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2027-08-11 F2 · shares: Reflects a reduction in the number of shares purchaseable under the stock option. A portion of the originally granted amount was void due to having exceeded certain plan limitations. F1 · derivative.exercise_date: The option award vests and becomes exercisable as follows (rounded up to the nearest whole share of common stock): one-third on August 11, 2018, then in 24 equal monthly installments on the 11th day of each subsequent calendar month, subject to the reporting person's continued service with the issuer. F2 · derivative.underlying_shares: Reflects a reduction in the number of shares purchaseable under the stock option. A portion of the originally granted amount was void due to having exceeded certain plan limitations. F2 · balance_after: Reflects a reduction in the number of shares purchaseable under the stock option. A portion of the originally granted amount was void due to having exceeded certain plan limitations. Read SEC document |
| June 15, 2017 Filed Jun 19, 2017 21:06 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $13.75 | $0.00 |
DisclosureSEC source: 0001209191-17-040878 · doc4.xml · derivative · entry 2 COLA MICHAEL F · CIK 0001188940 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2027-06-14 F2 · derivative.exercise_date: This option vests and becomes exercisable with respect to 100% of the option shares on June 15, 2018, provided that the Reporting Person has provided continuous service to the Issuer through the vesting date. Read SEC document |
| June 15, 2017 Filed Jun 19, 2017 21:06 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | GrantCommon Stock | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-040878 · doc4.xml · nonDerivative · entry 1 COLA MICHAEL F · CIK 0001188940 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 F1 · shares: Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 100% of the shares subject to this RSU will vest on June 15, 2018, provided that the Reporting Person has provided continuous service to the Issuer through the vesting date. Read SEC document |
| June 07, 2017 Filed Jun 8, 2017 23:37 UTC | Sage Therapeutics, Inc. SAGE · Entity 77038 | GrantStock Option (Right to Buy) · Derivative | 14,000 | $0.00 Strike: $72.74 | $0.00 |
DisclosureSEC source: 0001562180-17-002237 · primarydocument.xml · derivative · entry 1 COLA MICHAEL F · CIK 0001188940 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,000 Underlying: Common Stock · 14,000 shares Expires 2027-06-07 F1 · derivative.exercise_date: The stock option award was issued pursuant to the Sage Therapeutics, Inc., 2014 Stock Option and Incentive Plan. The option will vest in full upon the earlier to occur of June 7, 2018 or the day immediately prior to the 2018 Annual Meeting of Sage's stockholders, subject to continued service as a director on such date. Read SEC document |
| February 17, 2017 Filed Feb 17, 2017 17:44 UTC | Aevi Genomic Medicine, LLC GNMX · Entity 148532 | GrantStock Option (Right to Purchase) · Derivative | 250,000 | $0.00 Strike: $4.91 | $0.00 |
DisclosureSEC source: 0001192482-17-000047 · edgar.xml · derivative · entry 1 COLA MICHAEL F · CIK 0001188940 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2027-02-17 F1 · derivative.exercise_date: The option award vests and becomes exercisable in three equal installments (rounded up to the nearest whole share of common stock) on February 17, 2018, February 17, 2019 and February 17, 2020, subject to the reporting person's continued service with the issuer. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.